Suzanne Hendrix, Ph.D.
Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance- Estimating Accumulated or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials
Samuel Dickson, Ph.D.
Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved
Learning from failure: investigating reasons for failure of effective treatments identified in a meta-analysis of Alzheimer’s disease studies
Craig Mallinckrodt, Ph.D.
Statistical Approaches to Assess How Well Biomarker Results Predict Results on a Clinical Endpoint
Garrett Duncan, M.S.
Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer’s Disease
Caleb Dayley, M.S.
Breaking down the influences of placebo progression and percent slowing in the context of time saved in Alzheimer’s Disease clinical trials for populations in different disease stages
Abe Durrant, M.S.
Improving Study Power Through Continuous Modeling of a Global Treatment Effect Versus Composite Responder Analysis
Sam Johnson, M.S.
Rethinking Interim Analyses: When and Why to Avoid Them
Patrick O'Keefe, Ph.D.
Minimal clinically important differences are often misapplied and misinterpreted and should be used with caution
Joshua Christensen, M.S.
Improving insights on disease modification in Alzheimer’s disease by including sequential GSTs in the analysis hierarchy
Has Alzheimer’s been defined as a white person’s disease? How biomarker-based inclusion criteria may lead to differential access to clinical trials across racial and ethnic groups, an analysis of the Bio-Hermes study
John Whetten, M.S.
Estimating The 10-Year Time-Savings Benefits of Lecanemab Treatment
Abe Durrant, M.S.
Accelerated Approval in Alzheimer’s Disease: Lessons Learned and Future Directions
Sam Johnson, M.S.
A Statistical Evaluation of the Clinical Dementia Rating Global Score (CDR-GS) for Enhanced Clinical Outcome Assessment
Suzanne Hendrix, Ph.D.
Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance- Estimating Accumulated or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials
Samuel Dickson, Ph.D.
Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved
John Whetten, M.S.
Estimating The 10-Year Time-Savings Benefits of Lecanemab Treatment
